NEW YORK, April 18, 2017 /PRNewswire/ --
On Monday, April 17, 2017, US markets sawbroad based gains with nine out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,856.79, up 0.89%; the Dow Jones Industrial Average
Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock closed the day flat at $9.48. The stock recorded a trading volume of 5.04 million shares. The Company's shares are trading 24.93% and 50.01% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which operates as a pharmaceutical and medical device company worldwide, have a Relative Strength Index (RSI) of 26.73.
On March 23rd, 2017, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $21 a share to $18 a share. Visit us today and download your complete report on VRX for free at:
On Monday, shares in New York headquartered Delcath Systems Inc. ended the session 0.17% lower at $0.06 with a total volume of 8.29 million shares traded. Delcath Systems' shares are trading 57.58% below its 50-day moving average and 99.13% below its 200-day moving average. Moreover, shares of the Company, which operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver, have an RSI of 27.11. The complimentary research report on DCTH can be accessed at:
On Monday, shares in Dublin, Ireland headquartered Alkermes PLC recorded a trading volume of 583,059 shares. The stock ended the day 0.56% lower at $56.84. Alkermes' stock has gained 2.49% in the last three months and 43.43% in the previous one year. The Company's shares are trading above its 200-day moving average by 7.92%. Furthermore, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 45.02. Register for free on Stock-Callers.com and download the PDF research report on ALKS at:
Rancho Cucamonga, California headquartered Amphastar Pharmaceuticals Inc.'s stock finished Monday's session 0.54% higher at $14.88 with a total volume of 167,843 shares traded. Over the last one month and the previous one year, Amphastar Pharma's shares have gained 11.46% and 16.98%, respectively. The Company's shares are trading below its 50-day and 200-day moving averages by 1.01% and 15.57%, respectively. Shares of Amphastar Pharma, which focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products, are trading at a PE ratio of 66.13. The stock has an RSI of 50.42. Get free access to your research report on AMPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Vitamin A is an extremely vital vitamin needed for the eyes, skin, hair, immunity and during ...
Blood groups are of four important types determined by the presence or absence of specific ...View All